Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | CDK11B | P21127 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.32 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.32 |
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348778 | 0.98 | PDGFRB (0.46) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL627480 | 0.85 | PDGFRB (0.49) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336256 | 0.85 | MAPT (0.33) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336563 | 0.85 | PDGFRB (0.49) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949299 | 0.84 | PDGFRB (0.50) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL17517373 | 0.83 | DHFR (0.33) | EGFRMEN1KMT2AKCNK2KCNK10 | |
| SCHEMBL12336494 | 0.83 | PDGFRB (0.48) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL17658731 | 0.82 | PDGFRB (0.43) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336739 | 0.82 | PDGFRB (0.48) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949252 | 0.82 | DHFR (0.35) | EGFRMEN1KMT2AKCNK2KCNK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | claimed |
| WO-2012021778-A2 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | claimed |
| EP-2550266-B1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTICS SOLUTIONS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9260417-B2 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012021778-A2 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011119894-A2 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | KINAGEN, INC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011097594-A2 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | KINAGEN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | PDGFRB 486/4885KIT 799/4885PDGFRA 644/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | PDGFRB 486/4885KIT 799/4885PDGFRA 644/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | BRAF, BUB1B, MKI67 | PDGFRB 1405/4885KIT 1806/4885PDGFRA 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.